行情

EYEG

EYEG

Eyegate制药
NASDAQ

实时行情|Nasdaq Last Sale

5.88
+0.25
+4.44%
休市 16:00 01/24 EST
开盘
5.75
昨收
5.63
最高
6.49
最低
5.63
成交量
14.93万
成交额
--
52周最高
12.89
52周最低
2.250
市值
2,674.55万
市盈率(TTM)
-2.3979
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EYEG 新闻

  • WeWork与软银投资的Gympass签署共享办公空间协议
  • 新浪美股.2小时前
  • NBA神话人物陨落,球星科比坠机身亡
  • 第一财经.4小时前
  • 投资人科比:创办基金公司 投资阿里
  • 新浪科技综合.4小时前
  • 美国亚利桑那州确认第五例冠状病毒感染
  • 新浪财经.4小时前

更多

所属板块

制药
-1.84%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

EYEG 简况

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
展开

Webull提供Eyegate Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。